SEARCH

SEARCH BY CITATION

References

  • 1
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 15951607.
  • 2
    Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715722.
  • 3
    World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. World Health Organization, Geneva, 1999.
  • 4
    Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high Blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 24862497.
  • 5
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006; 23: 469480.
  • 6
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 16401645.
  • 7
    Committee for Japanese Definition of Metabolic Syndrome. Definition and criteria of metabolic syndrome. J Jpn Soc Int Med 2005; 94: 794809 (Japanese).
  • 8
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412419.
  • 9
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 14871495.
  • 10
    Yamada C, Mitsuhashi T, Hiratsuka N, et al. Optimal reference interval for homeostasis model assessment of insulin resistance (HOMA-IR) in a Japanese population. J Diabetes Invest 2011; Epub 3 April 2011; doi: 10.1111/j.2040-1124.2011.00113.x
  • 11
    Taniguchi A, Fukushima M, Sakai M, et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000; 23: 17661769.
  • 12
    Chang SA, Kim HS, Yoon KH, et al. Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea. Metabolism 2004; 53: 142146.
  • 13
    Masuo K, Katsuya T, Ogihara T, et al. Acute hyperinsulinemia reduces plasma leptin levels in insulin-sensitive Japanese men. Am J Hypertens 2005; 18: 235243.
  • 14
    Yoshitomi Y, Ishii T, Kaneki M, et al. Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects. J Atheroscler Thromb 2005; 12: 913.
  • 15
    Park H, Hasegawa G, Obayashi H, et al. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin Chim Acta 2006; 374: 129134.
  • 16
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157163.
  • 17
    Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 2005; 28: 22892304.
  • 18
    Coon PJ, Rogus EM, Drinkwater D, et al. Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age. J Clin Endocrinol Metab 1992; 75: 11251132.
  • 19
    Ryan AS. Insulin resistance with aging: effects of diet and exercise. Sports Med 2000; 30: 327346.
  • 20
    Bryhni B, Jenssen TG, Olafsen K, et al. Age or waist as determinant of insulin action? Metabolism 2003; 5: 850857.
  • 21
    Yamada C, Mitsuhashi T, Hiratsuka N, et al. Impact of insufficient insulin secretion on subclinical glucose dysregulation. Ningen Dock 2011; 25: 3744.
  • 22
    Yamada C, Mitsuhashi T, Hiratsuka N, et al. Determination of the optimal cut-off points for obesity-related measures of metabolic syndrome based on insulin resistance. Ningen Dock 2011; 25: 5359.
  • 23
    Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 16431649.
  • 24
    Tajiri Y, Sato S, Kato T, et al. Surrogate index for insulin sensitivity composed of factors not using glucose and insulin in Japanese patients with diabetes. J Diabetes Invest 2011; 2: 140147.